A human/murine chimeric fab antibody neutralizes anthrax lethal toxin in vitro

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Ding, Guipeng ^a   Chen, Ximin ^a   Zhu, Jin ^b   Duesbery, Nicholas S ^c   Cheng, Xunjia ^d   Cao, Brian ^c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Huadong Medical Institute of Biotechniques   (China)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

^d FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; BACTERIAL ANTIGEN; BACTERIAL TOXIN; HYBRID PROTEIN; NEUTRALIZING ANTIBODY;

ANTHRAX; ANTIBODY ENGINEERING; ARTICLE; BACILLUS ANTHRACIS; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CELL LINE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MACROPHAGE; MICROBIOLOGY; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; PROTEIN ENGINEERING; DRUG ANTAGONISM; DRUG EFFECT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BASE SEQUENCE; CELL LINE; ESCHERICHIA COLI; GENE EXPRESSION; IMMUNOGLOBULIN FAB FRAGMENTS; MACROPHAGES; MICE; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS;

EID: 84879297583     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/475809     Document Type: Article

References (40)

1. Tournier J., Ulrich R. G., Quesnel-Hellmann A., Mohamadzadeh M., Stiles B. G., Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis. Expert Review of Anti-Infective Therapy 2009 7 2 219 236 2-s2.0-64049107159 10.1586/14787210.7.2.219
2. Jernigan J. A., Stephens D. S., Ashford D. A., Anthrax bioterrorism investigation team. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerging Infectious Diseases 2001 7 6 933 944 10.3201/eid0706.010604
3. Sweeney D. A., Hicks C. W., Cui X., Li Y., Eichacker P. Q., Anthrax infection. American Journal of Respiratory and Critical Care Medicine 2011 184 12 1333 1341 2-s2.0-84455207436 10.1164/rccm.201102-0209CI
4. Bromberg-White J., Lee C., Duesbery N., Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin. Toxins 2010 2 5 1038 1053 2-s2.0-79952060991 10.3390/toxins2051038
5. Scobie H. M., Young J. A. T., Interactions between anthrax toxin receptors and protective antigen. Current Opinion in Microbiology 2005 8 1 106 112 2-s2.0-13444274554 10.1016/j.mib.2004.12.005
6. Moayeri M., Leppla S. H., The roles of anthrax toxin in pathogenesis. Current Opinion in Microbiology 2004 7 1 19 24 2-s2.0-1242351553 10.1016/j.mib.2003.12.001
7. Kronhardt A., Rolando M., Beitzinger C., Stefani C., Leuber M., Flatau G., Popoff M. R., Benz R., Lemichez E., Cross-reactivity of anthrax and C2 toxin: protective antigen promotes the uptake of botulinum C2I toxin into human endothelial cells. PLoS ONE 2011 6 8 2-s2.0-79961133761 10.1371/journal.pone. 0023133 e23133
8. Lim N. K., Kim J., Oh M. S., Lee S., Kim S., Kim K., Kang H., Hong H. J., Inn K., An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infection and Immunity 2005 73 10 6547 6551 2-s2.0-25444451322 10.1128/IAI.73.10.6547-6551.2005
9. Chen Z., Moayeri M., Zhao H., Crown D., Leppla S. H., Purcell R. H., Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding. Proceedings of the National Academy of Sciences of the United States of America 2009 106 32 13487 13492 2-s2.0-69449104867 10.1073/pnas.0906581106
10. Klinman D. M., Tross D., A single-dose combination therapy that both prevents and treats anthrax infection. Vaccine 2009 27 12 1811 1815 2-s2.0-61349104291 10.1016/j.vaccine.2009.01.094
11. Bienek D. R., Loomis L. J., Biagini R. E., The anthrax vaccine: no new tricks for an old dog. Human Vaccines 2009 5 3 184 189 2-s2.0-67549085292 10.4161/hv.5.3.7308
12. Cao S., Guo A., Liu Z., Tan Y., Wu G., Zhang C., Zhao Y., Chen H., Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination. Infection and Immunity 2009 77 10 4679 4687 2-s2.0-70349413068 10.1128/IAI.00264-09
13. Scobie H. M., Thomas D., Marlett J. M., Destito G., Wigelsworth D. J., Collier R. J., Young J. A. T., Manchester M., A soluble receptor decoy protects rats against anthrax lethal toxin challenge. Journal of Infectious Diseases 2005 192 6 1047 1051 2-s2.0-24644503512 10.1086/432731
14. Riddle V., Leese P., Blanset D., Adamcio M., Meldorf M., Lowy I., Phase I study evaluating the safety and pharmacokinetics of MDX-1303, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clinical and Vaccine Immunology 2011 18 12 2136 2142 2-s2.0-83455259467 10.1128/CVI.05059-11
15. Chen Z., Moayeri M., Crown D., Emerson S., Gorshkova I., Schuck P., Leppla S. H., Purcell R. H., Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infection and Immunity 2009 77 9 3902 3908 2-s2.0-69049106516 10.1128/IAI.00200-09
16. Pohl M. A., Rivera J., Nakouzi A., Chow S. K., Casadevall A., Combinations of monoclonal antibodies to anthrax toxin manifest new properties in neutralization assays. Infection & Immunity 2013 81 6 1880 1888 10.1128/IAI.01328-12
17. Azinovic I., DeNardo G. L., Lamborn K. R., Mirick G., Goldstein D., Bradt B. M., DeNardo S. J., Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunology, Immunotherapy 2006 55 12 1451 1458 2-s2.0-33748328199 10.1007/s00262-006-0148-4
18. Clementi N., Mancini N., Solforosi L., Castelli M., Clementi M., Burioni R., Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens. International Journal of Molecular Sciences 2012 13 7 8273 8292 10.3390/ijms13078273
19. Migone T., Subramanian G. M., Zhong J., Healey L. M., Corey A., Devalaraja M., Lo L., Ullrich S., Zimmerman J., Chen A., Lewis M., Meister G., Gillum K., Sanford D., Mott J., Bolmer S. D., Raxibacumab for the treatment of inhalational anthrax. The New England Journal of Medicine 2009 361 2 135 144 2-s2.0-67650500264 10.1056/NEJMoa0810603
20. Zhao P., Liang X., Kalbfleisch J., Koo H., Cao B., Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model. Human Antibodies 2003 12 4 129 135 2-s2.0-2442640131
21. Bromberg-White J. L., Duesbery N. S., Biological and biochemical characterization of anthrax lethal factor, a proteolytic inhibitor of MEK signaling pathways. Methods in Enzymology 2008 438 355 365 2-s2.0-45549106000 10.1016/S0076-6879(07)38025-7
22. Li C., Zhang F., Lin H., Wang Z., Liu X., Feng Z., Zhu J., Guan X., Generation and characterization of the human neutralizing antibody fragment Fab091 against rabies virus. Acta Pharmacologica Sinica 2011 32 3 329 337 2-s2.0-79952386111 10.1038/aps.2010.209
23. Zhu J., Kren B. T., Park C. W., Bilgim R., Wong P. Y.-P., Steer C. J., Erythroid-specific expression of β -globin by the sleeping beauty transposon for sickle cell disease. Biochemistry 2007 46 23 6844 6858 2-s2.0-34250200441 10.1021/bi6024484
24. Wang X., Zhu J., Zhao P., Jiao Y., Xu N., Grabinski T., Liu C., Miranti C. K., Fu T., Cao B. B., In vitro efficacy of immuno-chemotherapy with anti-EGFR human Fab-Taxol conjugate on A431 epidermoid carcinoma cells. Cancer Biology and Therapy 2007 6 6 980 986 2-s2.0-42449134890
25. Beatty J. D., Beatty B. G., Vlahos W. G., Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. Journal of Immunological Methods 1987 100 1-2 173 179 2-s2.0-0023258208
26. Abboud N., Casadevall A., Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background. Clinical and Vaccine Immunology 2008 15 7 1115 1123 2-s2.0-47649112407 10.1128/CVI.00015-08
27. Little S. F., Leppla S. H., Friedlander A. M., Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infection and Immunity 1990 58 6 1606 1613 2-s2.0-0025290784
28. Albrecht M. T., Li H., Williamson E. D., LeButt C. S., Flick-Smith H. C., Quinn C. P., Westra H., Galloway D., Mateczun A., Goldman S., Groen H., Baillie L. W. J., Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infection and Immunity 2007 75 11 5425 5433 2-s2.0-35649011984 10.1128/IAI.00261-07
29. Staats H. F., Alam S. M., Scearce R. M., Kirwan S. M., Zhang J. X., Gwinn W. M., Haynes B. F., In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infection and Immunity 2007 75 11 5443 5452 2-s2.0-35648942194 10.1128/IAI.00529-07
30. Kulshreshtha P., Bhatnagar R., Inhibition of anthrax toxins with a bispecific monoclonal antibody that cross reacts with edema factor as well as lethal factor of Bacillus anthracis. Molecular Immunology 2011 48 15-16 1958 1965 2-s2.0-80051936633 10.1016/j.molimm.2011.05.024
31. vor dem Esche U., Huber M., Zgaga-Griesz A., Grunow R., Beyer W., Hahn U., Bessler W. G., Passive vaccination with a human monoclonal antibody: generation of antibodies and studies for efficacy in Bacillus anthracis infections. Immunobiology 2011 216 7 847 853 2-s2.0-79957590835 10.1016/j.imbio.2010.12.001
32. Kacskovics I., Mayer B., Kis Z., Frenyó L. V., Zhao Y., Muyldermans S., Hammarström L., Cloning and characterization of the dromedary (Camelus dromedarius) neonatal Fc receptor (drFcRn). Developmental and Comparative Immunology 2006 30 12 1203 1215 2-s2.0-33746293842 10.1016/j.dci.2006.02.006
33. Kameyama S., Okada R., Kikuchi T., Omura T., Nakase I., Takeuchi T., Sugiura Y., Futaki S., Distribution of immunoglobulin Fab fragment conjugated with HIV-1 REV peptide following intravenous administration in rats. Molecular Pharmaceutics 2006 3 2 174 180 2-s2.0-33646383091 10.1021/mp050064m
34. Lim T. S., Mollova S., Rubelt F., Sievert V., Dübel S., Lehrach H., Konthur Z., V-gene amplification revisited-an optimised procedure for amplification of rearranged human antibody genes of different isotypes. New Biotechnology 2010 27 2 108 117 2-s2.0-77952243807 10.1016/j.nbt.2010.01.001
35. Chassagne S., Laffly E., Drouet E., Hérodin F., Lefranc M., Thullier P., A high-affinity macaque antibody Fab with human-like framework regions obtained from a small phage display immune library. Molecular Immunology 2004 41 5 539 546 2-s2.0-2942597518 10.1016/j.molimm.2004.03.040
36. Zhao Y., Gutshall L., Jiang H., Baker A., Beil E., Obmolova G., Carton J., Taudte S., Amegadzie B., Two routes for production and purification of Fab fragments in biopharmaceutical discovery research: papain digestion of mAb and transient expression in mammalian cells. Protein Expression and Purification 2009 67 2 182 189 2-s2.0-67650167709 10.1016/j.pep.2009.04.012
37. Acchione M., Lipschultz C. A., DeSantis M. E., Shanmuganathan A., Li M., Wlodawer A., Tarasov S., Smith-Gill S. J., Light chain somatic mutations change thermodynamics of binding and water coordination in the HyHEL-10 family of antibodies. Molecular Immunology 2009 47 2-3 457 464 2-s2.0-70450224882 10.1016/j.molimm.2009.08.018
38. Tang D., Zhang D., Tang D., Ai H., Amplification of the antigen-antibody interaction from quartz crystal microbalance immunosensors via back-filling immobilization of nanogold on biorecognition surface. Journal of Immunological Methods 2006 316 1-2 144 152 2-s2.0-33750018114 10.1016/j.jim.2006.08.012
39. Huang J., Liang J., Tang Q., Wang Z., Chen L., Zhu J., Feng Z., An active murine-human chimeric Fab antibody derived from Escherichia coli, potential therapy against over-expressing VEGFR2 solid tumors. Applied Microbiology and Biotechnology 2011 91 5 1341 1351 2-s2.0-80052632882 10.1007/s00253-011-3335-y
40. Wild M. A., Xin H., Maruyama T., Nolan M. J., Calveley P. M., Malone J. D., Wallace M. R., Bowdish K. S., Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nature Biotechnology 2003 21 11 1305 1306 2-s2.0-0242290931 10.1038/nbt891